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Background: Gastric inhibitory polypeptide 
(GIP) secreted from enteroendocrine 
K-cells potentiates insulin secretion and 
induces energy accumulation into adipose 
tissue.  
Results: Transcriptional factor Rfx6 is 
expressed in K-cells and increases GIP 
expression. Rfx6 expression is upregulated in 
K-cells of obese mice.  
Conclusion: Rfx6 plays critical roles in GIP 
expression and hypersecretion in obesity. 
Significance: Gene analysis of K-cells 
isolated from GIP-GFP knock-in mice 
enabled identification of Rfx6. 
 
SUMMARY 
Gastric inhibitory polypeptide (GIP) is an 
incretin released from enteroendocrine 
K-cells in response to nutrient ingestion. 
GIP potentiates glucose-stimulated insulin 
secretion and induces energy 
accumulation into adipose tissue, resulting 
in obesity. Plasma GIP levels are reported 
to be increased in the obese state. However, 
the molecular mechanisms of GIP 
secretion and high-fat diet (HFD)-induced 
GIP hypersecretion remain unclear, 
primarily due to difficulties in separating 
K-cells from other intestinal epithelial cells 
in vivo. In the present study, GIP-GFP 
knock-in mice that enable us to visualize 
K-cells by EGFP were established. 
Microarray analysis of isolated K-cells 
from these mice revealed that 
transcriptional factor regulatory factor X 
6 (Rfx6) is expressed exclusively in K-cells. 
In vitro experiments using mouse intestinal 
cell line STC-1 showed that knockdown of 
Rfx6 decreased mRNA expression, cellular 
content, and secretion of GIP. Rfx6 bound 
to the region in GIP promoter that 
regulates GIP promoter activity and 
over-expression of Rfx6 increased GIP 
mRNA expression. HFD induced obesity 
and GIP hypersecretion in GIP-GFP 
heterozygous mice in vivo. 
Immunohistochemical and flow cytometry 
analysis showed no significant difference 
in K-cell number between control-fat diet 
(CFD)-fed and HFD-fed mice. However, 
GIP content in upper small intestine and 
GIP mRNA expression in K-cells were 
significantly increased in HFD-fed mice 
compared to those in CFD-fed mice. 
Furthermore, expression levels of Rfx6 
mRNA were increased in K-cells of 
HFD-fed mice. These results suggest that 
Rfx6 increases GIP expression and content 
in K-cells and is involved in GIP 
hypersecretion in HFD-induced obesity.                                       
Obesity leads to insulin resistance 
characterized by fasting hyperinsulinemia 
and excessive insulin secretion to maintain 
euglycemia after meal ingestion (1). Obesity 
is an important risk factor in progression to 
type 2 diabetes mellitus (2) as well as 
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cardiovascular disease (3), and reduction of 
obesity can normalize hyperinsulinemia and 
impede the progression of diabetes and 
arteriosclerosis.  
Gastric inhibitory polypeptide, also called 
glucose-dependent insulinotropic polypeptide 
(GIP), and glucagon-like peptide-1 (GLP-1) 
are the incretins, peptide hormones released 
from the gastrointestinal tract into circulation 
in response to meal ingestion that potentiate 
glucose-stimulated insulin secretion (4, 5). 
GIP is secreted from enteroendocrine K-cells 
located in the duodenum and upper small 
intestine; GLP-1 is secreted from 
enteroendocrine L-cells located in lower 
small intestine and colon. GIP binds to the 
GIP receptor (GIPR) on the surface of 
pancreatic -cells, adipose tissue and 
osteoblasts, and stimulates insulin secretion 
(6), fat accumulation (7), and bone formation 
(8), respectively, by increasing the level of 
intracellular adenosine 3',5'-monophosphate 
(cAMP).  
It was reported previously that 
GIPR-deficient mice exhibit insufficient 
compensatory insulin secretion upon high-fat 
loading (9), suggesting that GIP plays a 
critical role in maintaining blood glucose 
levels by hypersecretion of insulin in 
diet-induced obesity. We also reported that 
sensitivity of GIPR to GIP in -cells is 
increased in high-fat diet (HFD)-induced 
obese mice (10). In addition, GIPR is 
expressed in adipose tissue (11), and 
increases glucose and triglyceride uptake in 
fat cells (12, 13). Thus, GIP has both direct 
and indirect effects on the accumulation of 
energy into adipose tissue. Some studies 
report that GIP secretion is increased in 
obesity (7, 14, 15, 16) and that pancreatic and 
duodenal homeobox 1 (Pdx1) , which is 
known to be an important transcription factor 
in pancreatic development and pancreatice 
β-cell maturation (17), has a critical role in 
GIP production in K-cells (18, 19). However, 
the mechanisms involved in GIP 
hypersecretion from K-cells in obesity 
remain unclear due to difficulties in 
separating these cells from other intestinal 
epithelial cells in vivo. 
In the present study, we investigated 
expression of various genes in K-cells by 
using GIP-GFP knock-in (GIP-GFP) mice in 
which K-cells can be visualized by EGFP 
fluorescence. We found that the 
transcriptional factor regulatory factor X 6 
(Rfx6) is expressed exclusively in K-cells of 
upper small intestine and is involved in GIP 
mRNA expression in the mouse small 
intestinal cell line STC-1. Furthermore, 
expression of Rfx6 as well as Pdx1 was 
found to be increased in K-cells of 
HFD-induced obese mice. Thus, GIP 
expression is stimulated by both Rfx6 and 
Pdx1, suggesting that these transcriptional 
factors play an important role in both GIP 
expression and GIP hypersecretion in 
HFD-induced obesity.  
 
EXPERIMENTAL PROCEDURES 
Animals― We designed targeting vector 
constructs  as short 
-EGFP-polyA-loxp-Neo-loxp-long cassettes 
using mouse B6N BAC Clone (ID: 
RP23-31E4 and RP23-383D10). A diphtheria 
toxin A expression cassette for negative 
selection was attached to the 3’ end of the 
GIP sequence in the targeting vector. Next, 
the targeting vector was injected in 
embryonic stem cells from C57BL6 mice and 
a Neo resistance strain was established. The 
ES cells positive for the knock-in gene were 
selected by southern blot analysis. The 
established ES cells were then injected into 
the blastocyst in order to obtain chimeric 
mice. Finally, we generated hetero-mutant 
mice by mating the chimeric mice with wild 
C57BL6. The mice were housed in an 
air-controlled (temperature 25°C) room with 
dark–light cycle of 10 h and 14 h, 
respectively. Animal care and procedures 
were approved by the Animal Care 
Committee of Kyoto University.    
GIP-GFP heterozygous mice (7 weeks of 
age) were fed control fat chow (CFD; 10% 
fat, 20% protein, and 70% carbohydrate by 
energy) or high fat chow (HFD; 60% fat, 
20% protein, and 20% carbohydrate by 
energy) (Research Diets Inc., New 
Brunswick, NJ) for 8 weeks. Food intake, 
water intake, and body weight were 
measured. 
Immunohistochemistry― Mouse upper 
small intestine samples were fixed in Bouin’s 
solution and transferred into 70% ethanol 
before processing through paraffin. 
Rehydrated paraffin sections were incubated 
overnight at 4°C with primary mouse 
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anti-GFP antibody (sc-9996, 1:100, Santa 
Cruz Biotechnology Inc., biotechnology, inc., 
CA) and rabbit anti-GIP antibody (T-4053, 
1:100, Peninsula Laboratories, Inc., San 
Carlos, CA). Intestine samples and STC-1 
cells (kindly provided by Prof. Hanahan, 
University of California, San Francisco) were 
embedded by Tissue-Tek O.C.T. compound 
4583 (Sakura Fine Technical Co. Ltd. Tokyo, 
Japan) and immediately frozen in liquid 
nitrogen. Frozen sections (10 m) on slides 
were air-dried and fixed in acetone for 5 min. 
Slides were then washed in PBS and blocked 
for 15 min in 3% BSA. They were incubated 
overnight at 4°C with primary antibody 
(Mouse anti-GIP antibody (1:100, kindly 
provided by Merck Millipore, Darmstadt, 
Germany) and goat anti-Rfx6 antibody 
(ABD28, 1:100, Merck Millipore)). The 
sections were incubated for 1 h at room 
temperature with secondary antibody. Images 
were taken using a fluorescent microscopy 
with a BZ-8100 system (KEYENCE 
Corporation, Osaka, Japan) and confocal 
microscopy with a LSM510META system 
(Carl Zeiss Co., Ltd., Jena, Germany).   
Fifty representative mucous membranes 
from each slide were randomly selected and 
their mean length and GFP-positive cells 
were quantified using fluorescent microscopy 
images. In order to count GFP-positive cells, 
we distinguished the mucous membrane as 
villus, upper crypt or lower crypt.  
Isolation of K-cells from mouse intestinal 
epithelium― Mouse upper small intestine 
was removed and washed by phosphate 
buffer saline (PBS). The intestine was cut 
into several round pieces and tied at one side 
with a thread. The pouch-like intestine was 
injected with Hanks balanced salt solution 
(HBSS) containing 0.5 mg / ml collagenase, 
clamped and incubated with CO2 at 37°C for 
10 min in Krebs-Ringer bicarbonate buffer 
(KRBB; 120 mM NaCl, 4.7 mM KCl, 1.2 
mM MgSO4, 1.2 mM KH2PO4, 2.4 mM 
CaCl2, 20 mM NaHCO3). The digested 
intestinal epithelium was collected into the 
tube filled with Roswell Park Memorial 
Institute (RPMI) medium and rinsed twice. 
The intestinal epithelium was cultured in a 
humidified incubator (95% air and 5% CO2) 
at 37°C for 1 h. Afterwards, it was 
centrifuged at 180 x g for 5 min, resuspended 
in PBS twice and filtered with a cell strainer 
(352340, BD Falcon cell strainer, Becton 
Dickinson and Company, San Jose, CA). 
GFP-positive cells in the intestinal epithelium 
were analyzed using BD FACS Aria™ flow 
cytometer (Becton Dickinson and Company). 
Sorted cells were collected into vials 
containing medium at a rate of 2000 cells / 
tube.      
Total RNA was extracted with PicoPure 
RNA isolation kit (Applied Biosystems, Inc, 
Alameda, CA) from sorted cells of GIP-GFP 
mice intestinal epithelium and treated with 
DNase (Qiagen Inc., Valencia, CA). 
Microarray analysis was performed using 
GeneChip Mouse Genome 430 2.0 Array 
(Affymetrix Inc., Fremont, CA).  
Glucose tolerance test (OGTT) and GIP 
assay― After a 16-h fasting period, oral 
glucose tolerance tests (OGTTs) (1 g / kg 
body weight) were performed. Blood samples 
were taken at the indicated times (0, 15, 30, 
60 and 120 min after glucose loading) and 
blood glucose levels, plasma insulin levels, 
and plasma total GIP concentrations were 
measured. Blood glucose levels were 
determined by the glucose oxidase method 
(Sanwa Kagaku Kenkyusho CO. LTD., 
Nagoya, Japan). Plasma insulin levels were 
determined using enzyme immunoassay 
(Shibayagi, Gumma, Japan). Plasma total 
GIP levels were determined using ELISA 
assay kit (Merck Millipore). 
For measurement of GIP content in 
mouse upper small intestine, the mice were 
killed at 15 weeks of age after 8 weeks of 
CFD or HFD feeding. The intestine was 
rapidly removed and washed by PBS. After 
measurement of the weight, samples were 
extracted with 5ml / g acid ethanol, and GIP 
levels were measured (15).   
Quantitative RT-PCR― Complementary 
DNA (cDNA) was prepared by reverse 
transcriptase (Invitrogen, Carlsbad, CA) with 
an oligo (dT) primer (Invitrogen). Messenger 
RNA (mRNA) levels were measured by 
quantitative RT-PCR using ABI PRISM 7000 
Sequence Detection System (Applied 
Biosystems Inc.). PCR analyses were carried 
out using the oligonucleotide primers. SYBR 
Green PCR Master Mix (Applied Biosystems 
Inc.) was prepared for PCR run. Thermal 
cycling conditions were denaturation at 95°C 
for 10 min followed by 50 cycles at 95°C for 
15 sec and 60°C for 1 min. C-terminal 
Rfx6 increases GIP mRNA expression in K-cells 
4 
 
and N-terminal primers of target 
molecules were designed as follows: GIP; 
Forward, 5’- gtggctttgaagacctgctc -3’, 
reverse, 5’- ttgttgtcggatcttgtcca -3’, GFP; 
5’- gtggctttgaagacctgctc -3’, reverse, 5’- 
tttacgtcgccgtccagctcg -3’, GLP-1; 5’- 
tgaagacaaacgccactcac -3’, reverse, 5’- 
tcatgacgtttggcaatgtt -3’, Pdx1; 5’- 
gacctttcccgaatggaa  -3, 5’- 
cttgttttcctcgggttc -3’, Rfx1; 5’- 
gcagccagaagcagtatgtg -3’, reverse, 5’- 
tggcttctgacacagtctcact -3’, Rfx2; 5’- 
cagaactccgagggaggag -3’, reverse, 5’- 
ggagggtgagtgtctgcatc -3’, Rfx3; 5’- 
cgtcacaggaggacaactca -3’, reverse, 5’- 
cagacttttgcagcgtctca -3’, Rfx4; 5’- 
ccgaatacactggccttagc -3’, reverse, 5’- 
atgggtgctcctcatacagg -3’, Rfx5; 5’- 
tctaccttcagctcccatcg -3’, reverse, 5’- 
ggcaggtatccatgtgctct -3’, Rfx6; 5’- 
acagacacggaatctgacat -3’, reverse, 5’- 
ctctaccacagtgtccaacc -3’, Rfx7; 5’- 
cgctctgcaacacaagatca -3’, reverse, 5’- 
gaccagaaggcagttgaagg -3’, GAPDH; 5’- 
aaatggtgaaggtcggtgtg -3’, reverse, 5’- 
tcgttgatggcaacaatctc -3’, 
Cell culture and small interfering RNA 
(siRNA) transfection into STC-1 cells― 
STC-1 cells, mouse small intestinal cell line, 
were cultured in Dulbeco’s modified Eagle’s 
medium (DMEM) (Sigma-Aldrich Co. LLC, 
St Louis, MO) supplemented with 10% 
heat-inactivated fetal calf serum, 100 IU / ml 
penicillin and 100 μg / ml streptomycin at 
37◦C in a humidified atmosphere (5% CO2 
and 95% air). siRNA transfection StealthTM 
siRNAs were synthesized (Invitrogen). The 
sequences of siRNAs specific for Rfx6 and 





STC-1 cells were trypsinized, suspended with 
DMEM medium without antibiotics, mixed 
with Opti-MEM (Invitrogen) containing 
siRNA and Lipofectamine TM2000 
(Invitrogen), plated on 12-well dishes, and 
then incubated at 37°C in a CO2 incubator. 
The amounts of STC-1 cells were 1 x 106 
cells / well. Medium was replaced with 1 ml 
DMEM containing antibiotics about 5-6 h 
after transfection. RT-PCR was performed 48 
h after transfection. 
Plasmid construction and transfection 
into STC-1 cells― The cDNA fragment of 
mouse Rfx6 protein was obtained from 
mouse (C57BL / 6) islets by RT-PCR. The 
cDNA fragment of Rfx6 was cloned into 
pCMV vector (Clontech Laboratories, 
Mountain View, CA). Expression 
plasmids of Rfx6 cDNA was transfected 
into STC-1 cells using Lipofectamine 
TM2000 (Invitrogen). Plasmid (8 µg / well) 
was diluted into Opti-MEM, and 
Lipofectamine TM2000 was added and 
incubated at room temperature for 20 
minutes. After incubation, the mixture 
was added to STC-1 cells (1 x 106 cells / 
well). RT-PCR was performed 48 h after 
transfection. 
Measurement of incretin release and 
cellular content in STC-1 cells― For incretin 
release assays, DMEM media were collected 
from STC-1 cells cultured on 12-well dishes 
about 42-43 h after changing the medium (48 
h after transfection). Media were centrifuged 
at 3,000 x g for 10 min and the supernatant 
was collected. Total GIP and Total GLP-1 
levels were measured by ELISA methods 
(Millipore and Meso Scale Discovery 
(Gaithersburg, MD), respectively) as incretin 
release from STC-1 cells. 
To determine incretin content, STC-1 
cells cultured on 12-well dishes (48 h after 
transfection) were washed with PBS and 
were homogenized in 0.5 ml of 0.1 N HCl 
and extracted at RT for 10 min, after which 
the supernatant was collected and centrifuged 
at 3,000 x g for 10 min. Incretin and protein 
levels were measured by ELISA assay (GIP 
and GLP-1) and Bradford reagent (Bio-Rad 
Laboratories, Inc, Hercules, CA), 
respectively.  
Yeast one-hybrid assay― Yeast 
one-hybrid assays were performed using 
the Matchmaker Gold Yeast One-Hybrid 
Library Screening System (Clontech 
Laboratories Inc., Mountain View, CA) 
according to the manufacturer’s protocol. 
The GIP promoter fragments shown in 
Fig.4A were inserted separately 
upstream of the aureobasidin A 
resistance gene on the pAbAi vector and 
Rfx6 cDNA was inserted downstream of 
GAL4-activating domain (GAL4AD) on 
pGADT7 AD vector. The interactions 
between GIP promoter fragments and 
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Rfx6-GAL4AD protein were assayed 
using the aureobasidin A resistance gene 
reporter system. First, S. cerevisiae 
Y1HGold (MAT, ura3-52, his3-200, ade2-101, 
trp1-901, leu2-3, 112, gal4, gal80, met- 
MEL1) were transformed by GIP 
promoter-fragment-inserted pAbAi 
plasmid (pAbAi-fragment a, b, c, and d), 
and spread on the synthetic medium with 
dextrose (SD) (without uracil) and 
incubated for 1 week at 30°C. Obtained 
yeast was transformed by Rfx6 
cDNA-inserted pGADT7 AD plasmid 
(pGADT7-Rfx6) and spread on the SD 
(without tryptophan) medium, and then 
incubated for 1 week at 30°C. Interaction 
between GIP promoter fragment and 
Rfx6-GAL4AD protein could be detected, 
and the transformant was grown on SD 
(without tryptophan) medium containing 
600 ng / ml aureobasidin A. 
GIP promoter activity― 1 x 106 STC-1 
cells were co-transfected with pGL4.19 
luciferase reporter plasmid expressing 
five different lengths of GIP promoter 
gene (Fig. 4C) and pGL4.73 renilla 
luciferase reporter plasmid. 48 h after 
transfection, luciferase and renilla 
activities were assayed according to the 
manufacturer’s protocol (Promega 
Corporation, Madison, WI) using a 
GioMax 20 / 20n luminometer (Promega). 
Firefly luciferase activity was normalized 
to renilla luciferase expression and is 
presented as fold increase in relative 
light units over samples transfected with 
pGL4.19. All samples were analyzed in 
duplicate. 
Analysis― The results are given as mean 
± standard error (SEM, n = number of mice). 
Statistical significance was determined using 
paired and unpaired Student’s t-test and 




Visualization and isolation of K-cells 
using GIP-GFP mice― GIP-GFP mice were 
generated for the purpose of visualizing 
enteroendocrine K-cells (Fig. 1A). The 
mouse GIP gene is composed of 6 exons. The 
targeting vector for GIP-GFP mice was 
designed so that EGFP cDNA is fused with 
exon 3 in the GIP gene. Prepro-GIP consists 
of 144 amino acids (Fig. 1B) and PC1/3 and 
PC2 cleave prepro-GIP, generating GIP 
(1-42) and GIP (1-30), respectively. In 
GIP-GFP mice, the fusion protein retains the 
signal peptide, but does not have the GIP 
(1-42) sequence nor the PC1/3 and PC2 
cleavage sites. Accordingly, GIP-GFP mice 
express GIP signal peptide-GFP fusion 
protein (280 amino acids). GFP fluorescence 
was observed in the small intestine of 
GIP-GFP heterozygous mice (Fig. 1C) and 
GIP-GFP homozygous mice (data not 
shown). 
Immunohistochemical analysis was 
performed to assess localization of 
GFP-expressing cells and GIP-expressing 
cells using anti-GFP and anti-GIP antibodies, 
respectively, in the upper small intestine of 
wild-type and GIP-GFP heterozygous and 
homozygous mice (Fig. 1D). GFP-expressing 
cells are present in the intestine of GIP-GFP 
heterozygous and homozygous mice and 
GIP-expressing cells are present in the 
intestine of both wild-type and GIP-GFP 
heterozygous mice. However, in GIP-GFP 
homozygous mice, no GIP-expressing cells 
were found. The GFP-expressing cells were 
identical to the GIP-expressing cells in 
GIP-GFP heterozygous mice. We then 
examined the fasting plasma GIP levels in the 
three types of mice (Fig. 1E). GIP levels were 
significantly lower in GFP-GFP heterozygous 
mice compared to those in wild-type mice. 
GIP levels of GIP-GFP homozygous mice 
were not detectable. These results indicate 
that GIP-GFP heterozygous mice have only 
one normal GIP gene and that GIP-GFP 
homozygous mice have no normal GIP gene.  
Next, GFP-positive cells were purified by 
a flow cytometry system. GFP-positive cells 
and GFP-negative cells from upper small 
intestinal epithelium of GIP-GFP 
heterozygous mice were separated and 
collected. GFP mRNA and GIP mRNA were 
highly expressed in GFP-positive cells (Fig. 
1F). In microarray analysis, the expression 
levels of GIP mRNA were much higher in 
GFP-positive cells than those in 
GFP-negative cells (GFP-positive cells (n=3) 
12951.55 + 335.77 vs. GFP-negative cells 
(n=3) 1763.61 + 142.65; P < 0.001). These 
results demonstrate that the GFP-positive 
cells in the intestinal epithelium of GIP-GFP 
mice are K-cells. 
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Transcription factor Rfx6 is expressed 
exclusively in K-cells― Microarray analysis 
data revealed that mRNA of the transcription 
factor Rfx6 is highly expressed in 
GFP-positive cells (GFP-positive cells (n=3) 
2613.4 + 341.9 vs. GFP-negative cells (n=3) 
24.0 + 6.7; P < 0.05). As seven members of 
the Rfx family were identified previously, we 
evaluated the expression of these mRNAs in 
mouse islets, GFP-positive cells (K-cells), 
and mouse small intestinal cell line STC-1 
(Fig. 2A). All of the Rfx genes, except for 
Rfx4, were expressed in islets as shown in a 
previous study (20). Rfx3, Rfx6, and Rfx7 
were expressed in GFP-positive cells, but no 
Rfx mRNAs were detected in the 
GFP-negative cells. In semi-quantitative 
RT-PCR data, the expression levels of Rfx6 
were extremely higher in GFP-positive cells 
than those in GFP-negative cells, while the 
expression levels of Rfx3 and Rfx7 were 
similar (Fig. 2B). Immunohistochemistry 
confirmed that Rfx6-expressing cells 
correspond to GFP-expressing cells (Fig. 2C), 
demonstrating that Rfx6 is expressed 
exclusively in K-cells.  
Inhibition of Rfx6 and Pdx1 expression 
decreases GIP expression in STC-1 cells― 
We then assessed the influence of Rfx6 on 
GIP expression and secretion by using STC-1 
cells. Rfx6 mRNA expression was confirmed 
in STC-1 cells by RT-PCR (Fig. 2A). The 
Rfx6-expressing cells were similarly located 
in the GIP-expressing cells by 
immunohistochemistry (Fig. 2D). By 
treatment with Rfx6 siRNA, Rfx6 mRNA 
expression was inhibited by 70% (Fig. 2E). 
In the same condition, mRNA expression, 
cellular content, and secretion of GIP were 
significantly decreased while those of GLP-1 
were similar to control (Fig. 2E, 2F and 2G), 
indicating that Rfx6 increases GIP mRNA 
expression, cellular content, and secretion. 
On the other hand, Pdx1 is reported to be an 
important transcriptional factor for producing 
GIP in K-cells (17, 18), although its 
expression levels were similar in 
GFP-positive and GFP-negative cells (Fig. 
3A). To examine the effect of Pdx1 on 
incretin expression and secretion, mRNA 
expression, cellular content, and secretion of 
GIP and GLP-1 were measured in 
Pdx1-knockdown STC-1 cells by using 
siRNA. Pdx1 mRNA expression was 
confirmed in STC-1 cells by RT-PCR (Fig. 
3B). The expression levels of Pdx1 mRNA 
were decreased by 50% in STC-1 cells 
treated with Pdx1 siRNA (Fig. 3C). GIP 
mRNA expression, cellular content, and 
secretion were significantly decreased, while 
GLP-1 mRNA expression, cellular content, 
and secretion were somewhat increased in 
STC-1 cells treated with Pdx1 siRNA (Fig. 
3C, 3D, and 3E). The expression levels of 
Rfx6 mRNA were significantly decreased in 
the cells (Fig. 3C).  
Interaction of Rfx6 and GIP gene― We 
assessed the interaction of the Rfx6 and 
GIP gene by one-hybrid assay. Four 
fragments of GIP promoter were 
constructed (Fig. 4A). Rfx6 effectively 
bound to fragment b (5216-6512 base 
pairs (bp) upstream of GIP promoter) (Fig. 
4B). In the luciferase promoter assay, GIP 
promoter activity of fragments A and B 
containing 5216-6512 bp upstream of GIP 
promoter was high, while the activities of 
GIP promoter C, D and E were 
significantly decreased (Fig. 4D). These 
results suggest that Rfx6 binds to the 
region 5216-6512 bp upstream of the GIP 
promoter, which regulates the GIP 
promoter activity. Furthermore, Rfx6 was 
over-expressed in STC-1 cells by 
transfection of Rfx6 expression plasmids. 
The expression levels of Rfx6 mRNA 
levels were significantly higher in Rfx6 
over-expressing cells compared to control 
(Fig. 4E). Rfx6 had no effect on the 
expression levels of to Pdx1 mRNA. GIP 
mRNA expression levels were 
significantly increased in Rfx6 
over-expressing cells, but GLP-1 mRNA 
expression levels were not (Fig. 4F).  
HFD-feeding increases GIP secretion and 
induces obesity and insulin hypersecretion in 
GIP-GFP heterozygous mice― To 
investigate the mechanisms of GIP 
hypersecretion in HFD-induced obesity in 
vivo, GIP-GFP heterozygous mice were fed 
CFD or HFD for 8 weeks. One week after 
starting with these diets, the body weight of 
the HFD group was significantly increased 
compared to that of CFD group (Fig. 5A). 
There was no difference in food and water 
intake between the CFD and HFD group 
(data not shown). After CHD- or HFD- 
feeding for 8 weeks, OGTTs were performed. 
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Blood glucose levels were significantly 
increased at 60 and 120 min during OGTT in 
HFD group (Fig. 5B). Insulin levels also 
were significantly increased in HFD group 
(Fig. 5C). Insulin secretion (AUC-insulin) of 
HFD group was increased about 5.5-fold 
compared to that of CFD group (CFD group 
(n=6) 38221 + 238 vs. HFD group (n=6) 
211835 + 456; P < 0.001). GIP 
concentrations of HFD group at 15, 30, and 
60 min were increased significantly 
compared to those of CFD group (Fig. 5D). 
GIP secretion (AUC-GIP) of HFD group was 
increased about 1.5-fold compared to that of 
CFD group (CFD group (n=6) 7368 + 123  
vs. HFD group (n=6) 10531 + 216; P < 0.05) 
These results show that HFD-feeding 
increases GIP secretion and induces obesity 
and insulin hypersecretion in GIP-GFP 
heterozygous mice, which have only one 
normal GIP gene.  
GIP hypersecretion in HFD-induced 
obese mice is not due to increase of K-cell 
number but to increase of GIP expression in 
K-cells― To determine whether GIP 
hypersecretion involves an increased number 
of K-cells in HFD-fed GIP-GFP 
heterozygous mice, the number and 
localization of the K-cells in the upper small 
intestine were estimated and compared. The 
length of mucous membrane and the number 
and localization of K-cells examined by 
immunohistochemistry were similar in the 
CFD and HFD group (Fig. 5E, 5F, and 5G). 
Flow cytometry analysis also showed no 
difference in K-cell number between the two 
groups (Fig. 5H). On the other hand, GIP 
content in upper small intestine was 
significantly increased in HFD group 
compared to that in CFD group (Fig. 5I). In 
addition, in K-cells purified using flow 
cytometry, the expression levels of GIP 
mRNA were almost 10-fold higher in HFD 
group than those in CFD group (Fig. 5J). 
These results demonstrate that GIP 
hypersecretion under HFD-induced obesity is 
not due to an increase in K-cell number but to 
an increase of GIP mRNA expression and 
content in K-cells. 
Rfx6 and Pdx1 mRNA levels were 
increased in K-cells of HFD-induced obese 
mice― We also assessed the expression of 
other candidate genes in K-cells 
(GFP-positive cells) (Fig. 5K) and 
non-K-cells (GFP-negative cells). Both Rfx6 
and Pdx1 mRNA levels were increased in 
K-cells of HFD group compared to those in 
K-cells of CFD group, but the mRNA 
expression levels of Rfx3 and Rfx7 were not. 
Other Rfx transcriptional factors (Rfx1, 2, 4 
and 5) were not detected in the K-cells of 
HFD-fed mice. Furthermore, none of the Rfx 
transcriptional factors were detected in 
non-K-cells. Pdx1 mRNA expression was 
detected in non-K-cells but there was no 
significant difference in the expression level 
between CHD group and HFD group (ratio of 
Pdx1 mRNA to GAPDH mRNA: CFD group 
(n=8) 0.47 + 0.15 vs. HFD group (n=8) 0.26 
+ 0.08; P = 0.24). These results strongly 
suggests that an increase in Rfx6 expression 
as well as Pdx1 expression in K-cells 
stimulate GIP mRNA expression and content 
in K-cells of HFD-fed obese mice.  
 
DISCUSSION 
Analysis of K-cells in vivo has been 
impossible due to inability to isolate the 
GIP-producing K-cells from intestinal 
epithelium. In the present study, GIP-GFP 
mice enabled sorting GFP-positive cells as 
K-cells and revealed that the transcription 
factor Rfx6 is expressed exclusively in 
K-cells by microarray analysis and RT-PCR 
(Fig. 2B). Rfx3 and Rfx7 also were detected 
in K-cells by RT-PCR, but there were no 
significant differences in their expression 
between K-cells and non-K-cells (Fig. 2B). 
The Rfx gene family of transcription factors 
was first detected in mammals as regulatory 
factors that bind to the promoter regions of 
major histocompatibility complex (MHC) 
class II genes (21); seven types of Rfx 
(Rfx1-7) have so far been identified. All Rfx 
transcriptional factors have a winged helix 
DNA binding domain. Rfx1, 2, 3, 4 and 6 
have a dimerization domain (22, 23), and 
Rfx6 forms homodimers or heterodimers 
with Rfx2 or Rfx3 (24, 25). Rfx6 was 
initially isolated from human genome 
sequences in 2008 (22). Serial Analysis of 
Gene Expression (SAGE) frequency data 
showed high expression of Rfx6 mRNA in 
pancreas, liver, and heart, and RT-PCR 
analysis showed high expression of Rfx6 
mRNA in human pancreas and intestine (20). 
On the other hand, it is known that Rfx3 
mRNA is expressed in brain, placenta, 
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pancreas, and pituitary, and that Rfx3 directly 
regulates the promoters of GLUT2 and 
glucokinase in pancreatic -cells (26). Rfx7 
is known to be expressed in many different 
tissues. Rfx3- and Rfx6-deficient mice were 
generated previously and none of the 
endocrine cells, excluding pancreatic 
polypeptide (PP)-expressing cells, are 
detected in the islets of these mice (20, 27). 
These results suggest that Rfx3 and Rfx6 
play a critical role in generating the 
endocrine cells in islets, but it is unknown 
whether they are associated with generation 
of enteroendocrine cells such as K-cells and 
L-cells. We examined incretin mRNA 
expression and content under inhibition of 
Rfx6 expression in STC-1 cells. Other 
incretin GLP-1 mRNA expression and 
content were preserved in Rfx6-knockdown 
STC-1 cells. On the other hand, GIP mRNA 
expression and content were significantly 
decreased in the cells (Fig. 2E, 2F, and 2G). 
In addition, Rfx3 expression tended to be 
higher in GFP-positive cells than that in 
GFP-negative cells (Fig. 2B), but GIP mRNA 
expression, content, and secretion were not 
changed in Rfx3-knockdown STC-1 cells 
(data not shown). These results suggest that 
Rfx6 expressed exclusively in K-cells plays 
an important role in GIP expression, cellular 
content, and secretion in K-cells. In addition, 
we examined the effect of Rfx6 on the GIP 
gene and found that Rfx6 binds to the 
region 5216-6512 bp upstream of GIP 
promoter gene (Fig. 4D) and that Rfx6 
increased GIP mRNA expression in 
STC-1 cells (Fig. 4F). Further study is 
needed to clarify the regulatory 
mechanism of GIP promoter activity by 
Rfx6. In previous studies, characterization of 
K-cells and microarray analysis were done 
using purified K-cells from the intestine of 
transgenic mice expressing a yellow 
fluorescent protein (YFP) under control of 
the 200 kb rat GIP promoter (28, 29), but 
Rfx6 expression in K-cells was not reported. 
The reason such a long promoter is required 
for specific expression of YFP in K-cells is 
not known, but it suggests that regulation of 
GIP gene expression is under complex 
control. In the present study, we established 
GIP-GFP mice in which GFP is under an 
endogenous, native promoter. Using these 
GIP-GFP mice, we were able to determine 
that Rfx6 is expressed exclusively in K-cells.  
In the previous studies, Pdx1 expression 
was detected in K-cells and Pdx1-deficient 
mice showed a greatly decreased number of 
GIP-expressing cells in the intestine (18, 19). 
It also has been reported that Pdx1 binds at 
150 bp upstream of GIP promoter and 
activates GIP promoter in STC-1 cells and 
that Pdx1 expression is essential for 
producing GIP in K-cells (18, 19). We found 
that there was no significant difference in 
Pdx1 mRNA expression between upper small 
intestinal K-cells and non-K-cells (Fig. 3A). 
These findings suggest the possibility that 
Rfx6 specifically expressed in K-cells plays a 
critical role in differentiation and GIP 
production of K-cells in collaboration with 
Pdx1. It was reported that Rfx6 mRNA 
expression is regulated by transcription factor 
Neurogenin 3 (Ngn3) in fetus pancreas (30). 
In another report, no colocalization of 
Pdx1-expressing cells and Rfx6-expressing 
cells was found in mouse fetus pancreas 
using immunohistchemistry analysis, and 
Pdx-1 expression was decreased in pancreas 
of Rfx6-defficient mice (20). In the present 
study, Pdx1 mRNA expression levels were 
not changed not in only Rfx6-knockdown 
STC-1 cells but also in Rfx6 over-expressing 
STC-1 cells, while Rfx6 expression levels 
were significantly decreased in 
Pdx1-knockdown STC-1 cells (Fig. 2E, Fig. 
3C, and Fig. 4E). These results suggest that 
Rfx6 expression is at least in part regulated 
by Pdx1.  
Increased blood GIP levels in obesity 
have been reported in several studies (7, 14, 
15, 16). There is a report that healthy human 
subjects administered high-fat food for 2 
weeks showed increased plasma GIP levels 
without developing obesity, suggesting that 
GIP hypersecretion precedes obesity (31). 
GIP is released from K-cells into circulation 
in response to various nutrients (32, 33, 34). 
Measurement of total GIP and total GLP-1 
levels in humans challenged with glucose or 
meal shows that the postprandial plasma GIP 
level is greatly augmented when a meal 
containing abundant fat rather than simple 
glucose is consumed (35, 36). This suggests 
that intake of HFD increases GIP secretion 
and strengthens both direct and indirect 
effects of GIP on energy accumulation in 
adipose tissue. We previously reported that 
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both GIP levels after glucose loading and 
BMI have a positive correlation in healthy 
subjects (37). In the present study, GIP levels 
during OGTT were increased in obese 
GIP-GFP heterozygous mice compared to 
those in lean GIP-GFP heterozygous mice, 
even though GIP-GFP heterozygous mice 
have only one normal GIP gene, indicating 
these mice represent a useful model for 
analysis of the mechanisms involved in the 
augmented GIP secretion in HFD-induced 
obesity. A previous study reported that 
augmentation of GIP secretion in 
HFD-feeding conditions is due to increased 
K-cell number (38). In that report, 
agglomerates of Pdx1- and GIP-double 
expressing cells were found inside the 
duodenal mucosa of obese rats after 
HFD-feeding. In the present study, however, 
we could not detect agglomerates of K-cells 
or an increase of K-cell number in duodenum 
or upper small intestine of HFD-fed GIP-GFP 
heterozygous mice by immunohistochemistry 
and flow cytometry analysis. The reason for 
this discrepancy could be difference of 
species, food composition, and / or duration 
of the HFD-feeding period. In our study, GIP 
content was significantly increased in the 
upper small intestine of HFD-fed mice 
compared to that in CFD-fed mice, and GIP 
mRNA expression was increased in K-cells 
of HFD-fed mice. These results suggest that 
GIP hypersecretion in HFD-induced obese 
mice is due to increased GIP expression in 
K-cells. In this condition, the expression 
levels of Rfx6 and Pdx1 mRNA were 
significantly increased in K-cells (Fig. 5K). 
As Rfx6 and Pdx1 were found to be 
important transcriptional factors in producing 
GIP in K-cells in our results using Rfx6 
knockdown and over-expression and in 
previous in vitro studies for Pdx1, an increase 
in Rfx6 and Pdx1 expressions might well be 
involved in GIP hypersecretion in K-cells in 
HFD-induced obese mice. 
In conclusion, gene analysis of K-cells 
isolated from GIP-GFP mice enables 
identification of the transcription factor 
Rfx6 which is expressed exclusively in 
K-cells and is involved in the regulation of 
GIP expression. We also show that 
expression of Rfx6 and Pdx1 is upregulated 
in K-cells of HFD-induced obese mice, 
which suggests that induction of Rfx6 as 
well as Pdx1 plays a critical role in GIP 
hypersecretion in HFD-induced obesity. 
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FIGURE 1. Gene construct of GIP-GFP mice. A. Wild-type GIP allele and targeted allele of 
GIP-GFP. EGFP-polyA-loxp-Neo-loxp cassette was inserted into exon 3 of wild-type GIP gene. 
B. Prepro GIP protein and GIP-GFP fusion protein. SP: signal peptide. Open triangle: PC1/3 
cleavage site, Closed triangle: PC2 cleavage site, Dotted line: amino acids of signal peptide, 
Solid line: translated protein from exon 3. C. Microscopic images of upper small intestine in 
GIP-GFP heterozygous mice (bright field image and fluorescence image). D. 
Immunohistchemical images of upper small intestine in wild-type (WT), GIP-GFP heterozygous 
(GIPgfp/+), and homozygous mice (GIPgfp/gfp). Green: GFP-expressing cells, Red: GIP-expressing 
cells, Yellow: Merged image. E. Fasting plasma GIP levels in WT, GIPgfp/+, and GIPgfp/gfp mice. F. 
GFP mRNA and GIP mRNA levels in GFP-positive cells (n=5-6) and GFP-negative cells 
(n=5-6). *P < 0.05, **P < 0.01, ***P < 0.001 
 
FIGURE 2. The effect of Rfx6 on mRNA expression, cellular content, and secretion of GIP in 
STC-1 cells. A. mRNA expression for Rfx genes 1-7 in islets, GFP-negative cells, GFP-positive 
cells, and STC-1 cells by PCR. B. Rfx3, Rfx6, and Rfx7 mRNA levels in GFP-positive cells 
(n=8-10) and GFP-negative cells (n=8-10). C. Immunohistchemical images of upper small 
intestine in GIP-GFP heterozygous mice. Green: GFP-expressing cells, Red: Rfx6-expressing 
cells, Yellow: Merged image. D. Immunohistchemical images of STC-1 cells. Green: 
GIP-expressing cells, Red: Rfx6-expressing cells, Yellow: Merged image. E. Rfx6, GIP, GLP-1 
and Pdx1 mRNA levels in Rfx6 knockdown STC-1 cells (n=4). F and G. Incretin content and 
secretion in Rfx6 knockdown STC-1 cells (n=4). *P < 0.05, **P < 0.01, n.s., not significance.  
 
FIGURE 3. The effect of Pdx1 on mRNA expression, cellular content, and secretion of GIP. A. 
Pdx1 mRNA levels in GFP-positive cells and GFP-negative cells (n=8-10). B. GIP, GLP-1, and 
Pdx1 mRNA expressions in STC-1 cells by RT-PCR. C. Pdx1, GIP, GLP-1, and Rfx6 mRNA 
levels in Pdx1 knockdown STC-1 cells (n=4). D and E. Incetin content and secretion in Pdx1 
knockdown STC-1 cells (n=4). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not significance. 
 
FIGURE 4. Interaction of Rfx6 and GIP gene. A. The design of the GIP promoter fragments for 
one-hybrid assay. Numbers indicate nucleotides upstream from the transcription start site of GIP 
gene. B. Results of yeast one-hybrid assay. Only yeast transformed with both pAbAi vector 
containing fragment b (pAbAi–fragment b) and Rfx6 cDNA-inserted pGADT7 (pGADT7-Rfx6) 
was grown on SD medium. C. The design of the different length of GIP promoter gene for luciferase 
reporter plasmid transfected in STC-1 cells. D. Luciferase promoter assay on GIP promoter. Data are 
represented by ratio of relative light unit (RLU) of Fragment E (n=3-4). *P < 0.05, n.s., not 
significance. E and F. Pdx1, Rfx6, GIP, and GLP-1 mRNA levels in Rfx6 over-expressing STC-1 
cells. **P < 0.01, ***P < 0.001 vs. control, n.s., not significance. 
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FIGURE 5. Analysis of K-cells in the small intestine of CFD- and HFD-fed GIP-GFP 
heterozygous mice (Histology, flow cytometry analysis, and gene expression). A. Body weight 
change of CFD-fed (dashed line) and HFD-fed (continuous line) GIP-GFP heterozygous mice 
(n=5-7). B, C and D. Blood glucose (B), insulin (C), and GIP levels (D) during OGTT after 8 
weeks of CFD- or HFD-feeding (n=5). Dashed line and white box shows CFD group, while 
continuous line and black box shows CFD group. *P < 0.05, **P < 0.01, ***P < 0.001 vs. 
CFD-fed mice. E. The length of mucous membrane in upper small intestine. (n=5). F. The 
number of GFP-positive cells by immunohistochemistry (n=5). G. The localization of K-cells in 
the upper small intestine by immunohistochemistry (n=5). H. The number of K-cells in the 
upper small intestine by flow cytometry analysis (n=5). I. GIP content in upper small intestine 
(n=5-7). J. GIP mRNA levels in GFP-positive cells (n=8-10). K. Pdx1, Rfx3, Rfx6, and Rfx7 
mRNA levels in GFP-positive cells (n=8-10). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not 
significance.   
 
 
 
 
 
